



PTO/SB/08A (02-03) Approved for use through 04/30/2003.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/004,832 INFORMATION DISCLOSURE December 7, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Ewen F. Kirkness Art Unit 1646 (use as many sheets as necessary) E. Kemmerer **Examiner Name** 2 1 of Attorney Docket Number PF105P1D2 Sheet

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
804	AA	5,270,452 B1	12-14-1993	Lim et al.	T igures / upocar		
1	AB	5,922,572 B1	07-13-1999	Rosen et al.			
	AC	5,986,069 B1	11-16-1999	Kirkness et al.			
	AD	6,346,246 B1	02-12-2002	Kirkness et al.			
	AE	09/912,292	Unpublished	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2;and SEQ ID NOS: 15797 and 15798		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear			
POL	AF	EP 0503297 A1	09-16-1992	Takeda Chemical Indus. Ltd.				
1	AG	EP 92102385.9	03-1992					
	AH	WO 91/16915	11-14-1991	Ciba Geigy AG		$\vdash$		
V	ΑI	WO 92/06712	04-30-1992	Amgen, Inc.				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
8216	AJ	BOSCH et al., "Axonal signals regulate expression of glia maturation factor beta in Schwann cells; an immunohistochemical study of injured sciatic nerves and cultured Schwann cells," The Journal of Neuroscience, 9(10):3690–3698 (1989).			
	AK	BOWIE et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," Science, 247:1306–1310 (1990).			
	AL	KAPLAN et al., "Molecular cloning and expression of biologically active human glia maturation factor-beta," Journal of Neurochemistry, 57:483–490 (1991).			
	AM	KELES et al., "Expression of glia fibrillary acidic protein in human medulloblastoma cells treated with recombinant glia maturation factor beta," Oncology Research, 4(10):431–437 (1992).			
	AN	LIM et al., "Antiproliferative function of glia maturation factor beta," Cell Regulation, 1:741–746 (1990).			
4	AO	LIM et al., "Cell-surface expression of glia maturation factor beta in astrocytes," The FASEB Journal, 4:3360–3363 (1990).			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

		_
Examiner a	Date	7
Signature C. A. IMAMIAM	Considered 9/24/63	
eignature C / CO// CV - COC-/	.   Considered	_

١,



Attachments

PTO/SB/08A (02-03)
Approved for use through 04/30/2003. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE for the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	estitute for form 1449/PTO			Complete if Known		
				Application Number	10/004,832	
IN	<b>NFORMATION</b>	N DI	SCLOSURE	Filing Date	December 7, 2001	
S	TATEMENT I	BY A	APPLICANT	First Named Inventor	Ewen F. Kirkness	
				Art Unit	1646	
	(use as many sheets as necessary)			Examiner Name	E. Kemmerer	
Sheet	2	of	2	Attorney Docket Number	PF105P1D2	

		OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
Elk	AP LIM et al., "Glia maturation factor beta regulates the growth of N18 neuroblastoma cells Developmental Biology, 137:444–450 (1989).						
ſ	AQ	LIM et al., "Purification and characterization of glia maturation factor beta: a growth regulator for neurons and glia," Proc. Natl. Acad. Sci. USA, 86:3901–3905 (1989).					
	AR	LIM et al., "Sequential interaction of glia maturation factor with insulin," Science, 1419–1420 (1984).					
	AS	LIM et al., "Structure and function of glia maturation factor beta," Plasticity and Regeneration of the Nervous System, 161–164 (1991).					
	AT	NGO et al., "Computational complexity, protein structure prediction, and the Levinthal paradox," The Protein Folding Problem and Tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, 491–5 (1994).					
	AU	NIETRO-SAMPEDRO et al., "Early release of glia maturation factor and acidic fibroblast growth factor after rat brain injury," Neuroscience Letters, 86:361–365 (1988).					
	AV	ZAHEER A. et al., "Expression of glia maturation factor beta mRNA and protein in rat organs and cells," J. of Neurochem., 60(3):914–920 (1993).					
	AW	GEORGE et al., "Current methods in sequence comparison and analysis," Macromolecular Sequencing and Synthesis: Selected Methods and Applications, D.H. Schlesinger, ed. Alan R. Liss, Inc. NY, 127–149 (1988).					
	AX	LIM et al., "Compete amino acid sequence of bovine glia maturation factor beta," Proc. Natl. Acad. Sci. USA, 7:5233–5237 (1990).					
	AY	LIM et al., "Glia maturation factor-beta promotes the appearance of large neurofilament-rich neurons in injured rat brains," Brain Research, 504:154–158 (1989).	-				
	AZ	WANG et al., "Polyclonal antibody localizes glia maturation factor beta-like immunoreactivity in neurons and glia," Brain Research, 591:1–7 (1992).					
	BA	Genbank Accession No. T65874 (02-21-1995).					
	BB	Genbank Accession No. AA297829 (04-18-1997).					
	BC	Genbank Accession No. T66033 (02-21-1995).					
	BD	Genbank Accession No. T51240 (02-06-1995).	<u></u>				
	BE	Genbank Accession No. AA297559 (04-18-1997).					
	BF	Genbank Accession No. AA297558 (04-18-1997).					
	BG	Genbank Accession No. T51355 (02-06-1995).					
	ВН	Genbank Accession No. Z11558 (02-10-1999).	ļ				
	BI	Genbank Accession No. M86492 (12-31-1994).					
	BJ	Genbank Accession No. S22149 (06-16-2000).	L				
	BK	Genbank Accession No. PT0410 (09-29-1999).	L				
	BL	Geneseq Accession No. R43941 (06-10-1994).	<u> </u>				
	ВМ	Geneseq Accession No. T19749 (07-11-1996).	<u> </u>				
<u> </u>	BN	Geneseq Accession No. Q53862 (06-10-1994).	<u> </u>				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner C T(2, 22, 22, 23, 23, 23, 23, 23, 23, 23, 2	Date		
	1	91	26/23
Signature 2. / Signature	Considered	ιį	a6/00